Need for concrete measures at national level to help stimulate innovation and ensure access for all European patients to modern medicines
10.10.2012, Brussels: EFPIA welcomes today’s Commission Communication on industrial policy as an important step to seeking to secure the competitiveness of the EU pharmaceutical industry and protect access to medicines for all of Europe’s citizens.
On Tuesday 2nd October MSF launched an online resource to help civil society groups and patient groups in developing countries to challenge unwarranted drug patents through patent oppositions.
22 November 2012 - Uppsala, Sweden
Organised by The Economist Group, Life Sciences Frontiers will take place in Uppsala Congress and Conference Centre in Uppsala, Sweden.
The event will explore radical and innovative ways of bringing together science and healthcare to address the challenge of creating high-quality patient-centric care at an affordable price.
Europe must make choices to remain a home for biomedical innovation.
The Commission proposal for a revised Transparency Directive (“the Proposal”) is an important and necessary step towards more efficient decision-making by member states in pricing and reimbursement (P&R) of medicines. At a time when countries across the EU are seeking improved management of their healthcare systems, it is essential that the procedural aspects of P&R decision-making are brought towards similar standards of quality and efficiency.
Check out what we are reading this week.